

Ø

Excelra's Target Dossier Services

Target identification is an essential first step toward the discovery and development of any new therapeutic. Consequently, successful pharma organizations perform due diligence around a target of interest before embarking on the long, time-consuming, expensive and high-risk endeavor of drug development. Clinical translatability to ensure that a drug's activity against the target is efficacious with minimal side effects, marks the crucial difference between success and failure of drug development.

Excelra's Custom Target Dossier Services

Excelra is strongly positioned to deliver tailor-made target assessment dossiers based on unique requirements of our global Biotech and Pharma clients. The dossier is a compendium of information on the complete target profile including structural, systemic and functional aspects of a protein and the gene-encoding it.

To facilitate critical 'Go/No-go decision making', we provide a 360-degree view of a target detailing:



Role in healthy tissues as well as its association with disease(s).

Molecular pharmacology, target expression across human tissues/organs, species, gene alterations and target interactions with other proteins/genes.

Competitive landscape of drug development by stage (approved, clinical & pre-clinical drugs).



Adverse events or toxicity data for compounds at any stage of development.

ON- and OFF- target safety assessment and de-risking strategies.





Sample Table of Contents

1. Target Profile
]_] Target Name
1.2 Protein Function
1.3 Synonyms
1.4 Genetic Identifiers
2. Structural characteristics-Domains etc.
3. Functional characteristics
4. Selectivity-Structural, Functional
5. Target Expression profile
6. Target Interactome
7. Target Genetics
7.1 Target associated gene
7.2 miRNAs associated with the target
7.3 Orthologs for the target
7.4 Paralogs for the target
7.5 Target associated Phenotypes

8. Target associated Ontologies and Pathways
8.1 GO Molecular Functions
8.2 GO Biological Processes
8.3 GO Cellular Component
8.4 Pathways
8.5 Bayesian Network Analysis
9. Target associated Diseases
9.1 Diseases associated with loss of Target activity
9.2 Diseases associated with genetic mutations in the Target
9.3 Diseases associated with Increased Target activity
10. Target associated Drugs
11. Phenotype associated with knockout or transgenic models
12. Target Safety and Toxicity
12.1 Systems biology information to assist in evaluation of safety liabilities
12.2 Bayesian Network Analysis
12.3 Hazard overview -Activation/Inhibition of Target
13. Target druggability

Excelra's Service Portfolio

	Insights	Data
Discovery	 Data Science Driven Drug Discovery Target Identification Target Dossier Services 	 Chemistry Curation Services GOSTAR Structure Activity Relationship database
Translational	 Biomarker Discovery Drug Repositioning Life Cycle Management Systems Biology Informatics 	 Biology Curation Services GOBIOM Biomarker intelligence database
ື່ຫຼືຕື້ຫຼື Clinical	 Precision Oncology Informatics Clinical Pharmacology	Clinical Trial Outcomes Database
Value Evidence	 Outcomes Research Epidemiology Modelling Economic Modelling Value Evidence Communication 	 RWE & Big Data Realization SLR & Meta-analysis
Technology Solutions	 Enterprise Data Strategy Enterprise Cloud Ops Enterprise Digital Transformation 	
Excelra Edge		



18+ Years Experience 15 of 20 Top Pharma Companies



60 PhDs and PharmDs

For more information, visit https://www.excelra.com/discovery/#target_dossier



About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients, including 15 of the top 20 large Pharma companies.